Author

J Pascual

Observed name: J. Pascual

Institution: Grifols (Spain)

Observed institution: Grifols (Spain)

OpenAlex ID: A5009223743

Letter: immunogenicity of infliximab originator vs. CT ‐P13 in IBD patients

2017 · G. Fiorino, C. Correale, et al. · Alimentary Pharmacology & Therapeutics · 8

P475 Switching from infliximab originator to CT-P13 is not related to increased immunogenicity in IBD patients: a prospective case-control study

2017 · G. Fiorino, S. Radice, et al. · Journal of Crohn s and Colitis · 3

Ab0369 Correlation of the First Lateral Flow-based Point of Care Test to Quantify Infliximab and Anti-infliximab Antibodies in a Finger Prick Sample With the Reference Elisa Technique

2022 · M.B. Ruiz-Argüello, J. Pascual, et al. · Annals of the Rheumatic Diseases · 2

P503 Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice

2017 · A. Ametzazurra, N. Rivera, et al. · Journal of Crohn s and Colitis · 2

Ab0354 Therapeutic Drug Monitoring: Performance of the First Lateral Flow-based Point of Care Test for the Quantification of Infliximab in a Finger Prick

2022 · A. Ametzazurra, J. Pascual, et al. · Annals of the Rheumatic Diseases · 1

P384 Therapeutic drug monitoring: performance of the first lateral flow-based Point of Care test for the quantification of infliximab in a finger prick

2021 · A Ametzazurra, J Pascual, et al. · Journal of Crohn s and Colitis · 1

P342 Correlation of the first lateral flow-based Point of Care test to quantify infliximab and anti-infliximab antibodies in a finger prick sample with the reference ELISA technique

2021 · M B Ruiz-Argüello, J Pascual, et al. · Journal of Crohn s and Colitis · 1

P605 Rapid detection of anti-infliximab antibodies in inflammatory bowel disease patients treated with the reference biologic or the biosimilar CT-P13: performance comparison with ELISA

2017 · G. Fiorino, A. Ametzazurra, et al. · Journal of Crohn s and Colitis · 1

PTU-087 Therapeutic cut-off of infliximab in patients with inflammatory bowel diseases

2015 · D Nagore, A Ruiz del Agua, et al. · Gut · 1

Ab0356 Therapeutic Drug Monitoring: Standardization of Promonitor Quick Ifx and Promonitor Quick Adl Point of Care Tests With Who International Standards for the Quantification of Infliximab and Adalimumab in Whole Blood and Serum

2022 · A. Ametzazurra, J. Pascual, et al. · Annals of the Rheumatic Diseases

P337 Therapeutic drug monitoring: standardization of Promonitor Quick IFX and Promonitor Quick ADL point of care tests with WHO International Standards for the quantification of infliximab and adalimumab in whole blood and serum

2022 · A Ametzazurra, J Pascual, et al. · Journal of Crohn s and Colitis

Enfermedad Inflamatoria Intestinal, Autocuidado y Calidad de Vida

2019 · Pesudo Francisco, J Pascual · Repositori UJI (Universitat Jaume I)

P546 Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease

2019 · N Torres, D Martín Arranz, et al. · Journal of Crohn s and Colitis

AB0656 Clinical Relevance of Measuring Free versus Total Anti-Infliximab Antibodies in Patients with Spondyloarthritis

2016 · A. Ruiz del Agua, J. Pascual, et al. · Annals of the Rheumatic Diseases

PTU-088 Method comparison study of assays for the determination of infliximab, adalimumab, and anti-drug antibody levels in patients with inflammatory bowel diseases

2015 · D Nagore, A Ruiz del Agua, et al. · Gut

Works count: 15

Citation count: 20

H-index: 2

I10-index: